Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: Mol Cancer Res. 2013 Jun 10;11(9):1004–1016. doi: 10.1158/1541-7786.MCR-13-0114

Figure 6. Plerixafor decreases stromal protection and increases chemosensitivity in MOLM-14 with chemotherapy-induced upregulation of surface CXCR4.

Figure 6

Figure 6

Figure 6

Figure 6

Figure 6

(a) MOLM-14 cells were pretreated with vehicle control or chemotherapy for 72 hours. Surface CXCR4 expression in live cells was measured by flow cytometry. (b-e) Viable cells were plated on stroma and treated with a dose range of daunorubicin with or without 5 μmol/L plerixafor. Following treatment, cells were harvested and stained with Annexin V and 7-AAD. Viable cells are negative for both Annexin V and 7-AAD. Results after pretreatment with (b) vehicle control, (c) daunorubicin, (d) vincristine, and (e) cytarabine are shown. P values compare overall treatment effects by chemotherapeutic agent of the stroma vs. stroma + plerixafor culture conditions.